2018 Top Story- Archives -
Top story: FDA approves first drug to use RNA interference, based on discoveries made at UMass Medical School
The new drug, patisiran, approved Aug. 10 by the FDA, is based on the discovery of RNAi made by Craig Mello, PhD, and Andrew Fire, PhD. It was developed by Alnylam, an RNAi-based drug development company co-founded by Phillip Zamore, PhD.
The annual U.S. News & World Report rankings of the best graduate schools names UMass Medical School in the top 10 percent nationwide in primary care, coming in 14th among 144 medical schools and 33 schools of osteopathic medicine surveyed by the weekly news magazine in its 2019 edition of the “Best Graduate Schools.”
Top story: UMass Medical School scientists safely deliver RNAi-based gene therapy for ALS in animal model
A gene therapy delivered to motor neurons was able to silence SOD1 protein, mutations of which are linked to ALS, without causing any adverse effects, according to a new study published in Science Translational Medicine, by Christian Mueller, PhD, and Robert H. Brown Jr., DPhil, MD.
Top story: UMass Medical School researchers explain why cannabis may relieve intestinal inflammation
Beth McCormick, PhD, led a study that has for the first time identified a biological mechanism to explain why some marijuana users have reported beneficial effects from cannabis on conditions such as ulcerative colitis and Crohn’s disease.
John E. Harris, MD, PhD, and colleagues have made a promising discovery that could lead to therapies for vitiligo with longer-lasting effects, according to new research published in Science Translational Medicine on July 18.
The single-minded goal of cardiologist and scientist Jane Freedman, MD, is to seek insights that will help heal patients with heart disease. Learn about her research and career in the latest Women in Science video.
Axovant Sciences, a Swiss company developing gene therapies for neurological diseases, has licensed exclusive worldwide rights for the development and commercialization of two novel gene therapy programs for Tay-Sachs and Sandhoff diseases from UMass Medical School.
Led by Guangping Gao, PhD, and Erik Sontheimer, PhD, scientists at UMass Medical School will work to develop technology to enable safe genome editing in patients, thanks to new grant funding from the National Institutes of Health.
Jeanne Lawrence, PhD, and Jaime Rivera, PhD, received a five-year, $2.8 million grant from the Eunice Kennedy Shriver National Institute of Child Health & Human Development at the National Institutes of Health to test a strategy in a mouse model for silencing the extra chromosome that causes Down Syndrome.
Victor Ambros, PhD, has been elected by his peers as a fellow of the American Association for the Advancement of Science.